Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib malate before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving sunitinib malate after surgery may kill any tumor cells that remain after surgery.

PURPOSE: This phase II trial is studying how well giving sunitinib malate before and after surgery works in treating patients with metastatic kidney cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Determine if neoadjuvant sunitinib malate can achieve a clinical benefit of 70% or more to the primary renal tumor prior to surgery and adjuvant sunitinib malate in patients with metastatic renal cancer.

Secondary

* Determine the time to radiological progression in these patients.
* Determine the overall survival of these patients.
* Determine the proportion of patients suitable for nephrectomy after neoadjuvant sunitinib malate.
* Determine the translational endpoints.

OUTLINE: Patients receive oral sunitinib malate once daily on days 1-28. Treatment repeats every 6 weeks for 3 courses. Approximately 2 weeks later, patients undergo a standard radical nephrectomy with lymph node dissection. Beginning at least 2 weeks after surgery, patients receive oral sunitinib malate on days 1-28. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

Blood and tissue samples may be collected periodically for laboratory studies.

After completion of study treatment, patients are followed every 2 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

clear cell renal cell carcinoma stage IV renal cell cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

sunitinib malate

Intervention Type DRUG

laboratory biomarker analysis

Intervention Type OTHER

adjuvant therapy

Intervention Type PROCEDURE

neoadjuvant therapy

Intervention Type PROCEDURE

therapeutic conventional surgery

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed renal cell carcinoma

* Measurable metastatic disease on CT/MRI imaging
* Patients with suspicion of renal cancer on radiology must have a biopsy to confirm diagnosis of clear cell disease
* No prior therapy for renal cancer
* Judged by the treating physician to have the potential to derive clinical benefit from this treatment

PATIENT CHARACTERISTICS:

* ECOG performance status 0-2
* Absolute neutrophil count ≥ 1 x 10\^9/L (without growth factor support)
* Platelet count ≥ 75 x 10\^9/L
* Total bilirubin ≤ 2 times upper limit of normal (ULN) (except for patients with Gilbert disease)
* Serum creatinine ≤ 2 times ULN
* Serum transaminases \< 5 times ULN
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for ≥ 28 days after completion of study therapy
* Willing and able to comply with scheduled visits, treatment plan, and laboratory tests and other study procedures
* No congestive heart failure, myocardial infarction, or coronary artery bypass graft within the past 6 months, or ongoing severe or unstable arrhythmia requiring medication
* No other severe acute or chronic medical or psychiatric condition, or abnormal laboratory results that would impart, in the judgement of the investigator, excess risk associated with study participation or study drug administration or would make the patient inappropriate for entry into this study

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* At least 7 days since prior and no concurrent potent CYP3A inhibitors, including any of the following:

* Ketoconazole
* Itraconazole
* Clarithromycin
* Erythromycin
* Diltiazem
* Verapamil
* Delavirdine
* Indinavir
* Saquinavir
* Ritonavir
* Atazanavir
* Nelfinavir
* At least 12 days since prior and no concurrent potent CYP3A inducers, including any of the following:

* Rifampin
* Rifabutin
* Carbamazepine
* Phenobarbital
* Phenytoin
* St. John's wort
* Efavirenz
* Tipranavir
* Concurrent radiotherapy allowed provided sunitinib malate is stopped one day before and resumed one day after radiotherapy
* Concurrent coumarin-derivative anticoagulants (e.g., warfarin) allowed (≤ 2 mg/day) for prophylaxis of thrombosis
* No concurrent treatment with a drug having proarrhythmic potential (i.e., terfenadine, quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, or flecainide)
* No other concurrent investigational drug or participation in another clinical trial (unless approved by the sponsor)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Thomas Powles, MD, MRCP

Role: PRINCIPAL_INVESTIGATOR

Barts and the London School of Medicine and Dentistry

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Orchid Clinical Trials Group at Barts and the London School of Medicine and Dentistry

London, England, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Powles T, Chowdhury S, Bower M, Saunders N, Lim L, Shamash J, Sarwar N, Sadev A, Peters J, Green J, Boleti K, Augwal S. The effect of sunitinib on immune subsets in metastatic clear cell renal cancer. Urol Int. 2011;86(1):53-9. doi: 10.1159/000319498. Epub 2010 Oct 26.

Reference Type RESULT

PMID: 20975250 (View on PubMed)

Stewart GD, Powles T, Van Neste C, Meynert A, O'Mahony F, Laird A, Deforce D, Van Nieuwerburgh F, Trooskens G, Van Criekinge W, De Meyer T, Harrison DJ. Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer. Oncotarget. 2016 May 3;7(18):25241-50. doi: 10.18632/oncotarget.8308.

Reference Type DERIVED

PMID: 27029034 (View on PubMed)

Stewart GD, O'Mahony FC, Laird A, Rashid S, Martin SA, Eory L, Lubbock AL, Nanda J, O'Donnell M, Mackay A, Mullen P, McNeill SA, Riddick AC, Aitchison M, Berney D, Bex A, Overton IM, Harrison DJ, Powles T. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur Urol. 2014 Nov;66(5):956-63. doi: 10.1016/j.eururo.2014.04.007. Epub 2014 May 10.

Reference Type DERIVED

PMID: 24821582 (View on PubMed)

Shaw GL, Hussain M, Nair R, Bycroft J, Beltran L, Green JS, Powles T, Peters JL. Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective. Urol Int. 2012;89(1):83-8. doi: 10.1159/000338057. Epub 2012 May 16.

Reference Type DERIVED

PMID: 22614181 (View on PubMed)